secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001070081-25-000014
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC518 Phase 2 PIVOT-HD meets primary endpoint with dose-dependent HTT lowering at Week 12
--------------------------------------------------------------------------------

- Primary endpoint met: dose-dependent blood HTT protein reduction (p<0.0001) at Week 12.
- 5mg dose lowered HTT 23% in Stage 2/3; 10mg lowered 39% (Stage 2) and 36% (Stage 3).
- Favorable dose-dependent trends on cUHDRS, TFC, SDMT in Stage 2 patients at 12 and 24 months.
- No treatment-related SAEs or NfL spikes; safety and tolerability profile favorable.
- At Month 24, dose-dependent NfL lowering: -8.9% (5mg, p=0.12) and -14% (10mg, p=0.03) vs natural history.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008125000014/0001070081-25-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008125000014/tmb-20250505x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-25-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer